The human body's intricate defense mechanisms never cease to amaze, and a recent study has shed light on a hidden army of immune cells that safeguard our lungs from a multitude of pathogens. Researchers have discovered that the lungs act as a reservoir for tissue-resident memory T cells (TRM cells), a specialized type of T cell that provides long-lasting protection against a surprising array of viruses, bacteria, and fungi.
What makes this finding particularly intriguing is the fact that these TRM cells are exclusive to the lungs and don't appear in blood samples. This unique residency allows them to persist in the lungs for extended periods, even years, without showing up in mice, which are commonly used in preclinical research. This highlights the importance of studying human immunology directly, as emphasized by study leader Pandurangan Vijayanand, MD, PhD.
The study, published in Nature Immunology, involved examining over 87,000 lung TRM cells from 40 human participants, aged 61 to 83. The researchers found that these TRM cells were ready to combat a wide range of respiratory pathogens, including influenza type A, SARS-CoV-2, parainfluenza virus, respiratory syncytial virus (RSV), metapneumovirus (MPV), cytomegalovirus (CMV), Epstein Barr virus (EBV), Bordetella pertussis (whooping cough), and Aspergillus fumigatus (a common fungus that can cause severe infections in immunocompromised individuals).
This discovery underscores the body's remarkable ability to build up immunity over time, as evidenced by the presence of TRM cells targeting various pathogens. The findings also have significant implications for vaccine research, suggesting that examining lung T cells, rather than just blood samples, may be crucial for understanding how to boost immunity directly in the respiratory system.
Furthermore, the study highlights a critical biological difference between human subjects and mouse models of disease. Human TRM cells remain in the lungs for months or years, whereas mouse TRM cells undergo rapid attrition. This discrepancy emphasizes the need for more closely examining human lung tissue samples in future TRM cell research and preclinical vaccine studies.
The research was supported by various grants from the National Institutes of Health and the William K. Bowes Jr Foundation, with sample collection facilitated by the North West and South Central Research Delivery Networks, National Institute of Health Research, UK. The study's findings open up exciting avenues for further exploration, particularly in understanding the long-term impact of vaccines on TRM cells in the lungs and their role in preventing severe respiratory infections.
